Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF‐1α‐induced pro‐angiogenic factor

• Published in: Cancer science Vol. 109; no. 5; pp. 1627 - 1637
• Main Authors: Wang, Ji‐Chang, Li, Xiong‐Xiong, Sun, Xin, Li, Guang‐Yue, Sun, Jing‐Lan, Ye, Yuan‐Peng, Cong, Long‐Long, Li, Wei‐Ming, Lu, Shao‐Ying, Feng, Jun, Liu, Pei‐Jun
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2018; John Wiley and Sons Inc
• Subjects: AMP; AMP-Activated Protein Kinases - antagonists & inhibitors; AMP-Activated Protein Kinases - physiology; AMPK; Angiogenesis; Animals; Antibodies; anti‐angiogenesis; Breast cancer; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug dosages; Endothelial cells; Enzyme Activation - drug effects; Female; Fibroblast Growth Factor 2 - analysis; Fibroblast growth factors; HIF‐1α; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit - physiology; Kinases; Lectins; Medical research; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic - prevention & control; Original; Phosphorylation; Proteins; Simvastatin; Simvastatin - pharmacology; Smooth muscle; statin; Statins; Statistical analysis; Transcription; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - analysis; United States > US; simvastatin; AMPK; HIF-1α; statin; anti-angiogenesis

Substantial data from preclinical studies have revealed the biphasic effects of statins on cardiovascular angiogenesis. Although some have reported the anti‐angiogenic potential of statins in malignant tumors, the underlying mechanism remains poorly understood. The aim of this study is to elucidate...